[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336280-105":59,"doc-detail-336280-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sting-activation-reprograms-the-microenvironment-to-sensitize-nf1-related-malignant-peripheral-nerve-sheath-tumors-for-immunotherapy","STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy","","Neurofibromatosis type 1 (NF1) results from loss-of-function mutations in NF1, leading to hyperactive RAS signaling and the emergence of malignant peripheral nerve sheath tumors (MPNSTs), which are aggressive, difficult to resect, and resistant to chemo- and radiotherapy. Although immune checkpoint blockade (ICB) can treat otherwise inoperable cancers, effective responses require an immune cell–rich tumor microenvironment. MPNSTs are typically noninflamed “cold” tumors, limiting checkpoint efficacy. This work shows that activating STING signaling converts MPNSTs into T cell–inflamed “hot” tumors, enhancing apoptotic cell death in mouse genetic and human xenograft models treated with a STING agonist plus ICB, yielding tumor growth delay and supporting a potential treatment regimen.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sting-activation-reprograms-the-microenvironment-to-sensitize-nf1-related-malignant-peripheral-nerve-sheath-tumors-for-immunotherapy/336280/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sting-activation-reprograms-the-microenvironment-to-sensitize-nf1-related-malignant-peripheral-nerve-sheath-tumors-for-immunotherapy/336280.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What causes neurofibromatosis type 1 and how does it relate to MPNST development?","Question",{"text":112,"@type":113},"NF1 is caused by mutations in the NF1 gene that disrupt neurofibromin, a RAS GTPase–activating protein. Loss of NF1 increases RAS-mediated signaling and contributes to the development of multiple neoplasms, including MPNSTs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are immune checkpoint blockade therapies difficult to apply to MPNSTs?",{"text":117,"@type":113},"The document states that MPNSTs are typically non–T cell–inflamed “cold” tumors. Because successful ICB outcomes require a T cell–enriched tumor microenvironment, cold tumors are less likely to generate effective antitumor responses to checkpoint inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"How does STING activation improve response to immunotherapy in the described models?",{"text":121,"@type":113},"By activating STING signaling, the strategy converts MPNSTs into T cell–inflamed “hot” tumors. In mouse genetic and human xenograft models, combining a STING agonist with ICB produced growth delay associated with increased apoptotic cell death.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336280,1790128390,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nSTING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nervesheath tumors for immunotherapy  \nBandarigoda N. Somatilaka,1 Laasya Madana,1 Ali Sadek,1 Zhiguo Chen,1 Sanjay Chandrasekaran,2,3 Renee M. McKay,1 and Lu Q. Le1,2,4,5,6,7 1Department of Dermatology, 2 Simmons Comprehensive Cancer Center, 3Department of Internal Medicine, Division of Hematology/Oncology, 4University of Texas Southwestern Comprehensive Neurofibromatosis Clinic, 5Hamon Center for Regenerative Science and Medicine, and 6O’Donnell Brain Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA. 7Department of Dermatology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.  \nNeurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene that encodes neurofibromin, a RAS GTPase–activating protein. Inactivating NF1 mutations cause hyperactivation of RAS-mediated signaling, resulting in the development of multiple neoplasms, including malignant peripheral nerve sheath tumors (MPNSTs) . MPNSTs are an aggressive tumor and the main cause of mortality in patients with NF1. MPNSTs are difficult to resect and refractory to chemo-and radiotherapy, and no molecular therapies currently exist. Immune checkpoint blockade (ICB) is an approach to treat inoperable, undruggable cancers like MPNST, but successful outcomes require an immune cell–rich tumor microenvironment. While MPNSTs are noninflamed “cold”tumors, here, we converted MPNSTs into T cell–inflamed “hot” tumors by activating stimulator of IFN genes (STING) signaling. Mouse genetic and human xenograft MPNST models treated with a STING agonist plus ICB exhibited growth delay via increased apoptotic cell death. This strategy offers a potential treatment regimen for MPNSTs.  \nIntroduction  \nNeurofibromatosis type 1 (NF1) affects 1 in 3,000 individuals. A hallmark feature of NF1 is the development of benign cutaneous and plexiform neurofibromas (pNFs) that arise in the skin and peripheral nerve plexuses, respectively. In up to 10% of patients with NF1, benign pNFs undergo transformation into malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive and are the leading cause of death inpatients with NF1 (1).  \nNF1 is associated with inactivating mutations in the NF1 gene that encodes neurofibromin, a RAS GTPase–activating protein. Neurofibromin binds to the GTP-bound active form of RAS and enhances GTPase activity, negatively regulating downstream signaling. As a result, inactivating mutations inNF1 activate multiple effector cascades including the RAS/RAF/MEK/ERK and PI3K/ AKT/mTOR pathways (2). Inhibition of RAS and RAS-activated downstream signaling pathways have been explored as treatments for MPNST, however, these efforts have been unsuccessful, yielding no significant improvement in survival for patients with MPNST in clinical trials (3–5). The MEK inhibitor selumetinib is currently the only FDA-approved drug for the treatment of NF1-associated inoperable pNF, but it is not effective against MPNST (6–9) . To date, pharmacologic targeting of dysregulated signaling pathways remains an unsuccessful strategy to treat  \nConflict of interest: The authors have declared that no conflict of interest exists. Copyright: © 2024, Somatilaka et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: October 18, 2023; Accepted: March 12, 2024; Published: March 19, 2024.  \nReference information: J Clin Invest. 2024;134(10):e176748 .  \n[h](https://doi.org/10.1172/JCI176748)[ttps://doi.org/10.1172/JCI176748](https://doi.org/10.1172/JCI176748) .  \nMPNST. Surgical resection, therefore, remains the primary treatment for MPNST, although achieving complete tumor removal is often challenging, given the large size of the tumor and/or its proximity to nerves (10, 11). Additionally,","cbCailEhhQGWIqCW","https://ap.wps.com/l/cbCailEhhQGWIqCW","pdf",18080570,13,"English","# Introduction\n## NF1 and MPNST background\n## Therapeutic challenges and immune checkpoint blockade\n## Rationale for converting “cold” tumors to “hot” tumors","[{\"question\":\"What causes neurofibromatosis type 1 and how does it relate to MPNST development?\",\"answer\":\"NF1 is caused by mutations in the NF1 gene that disrupt neurofibromin, a RAS GTPase–activating protein. Loss of NF1 increases RAS-mediated signaling and contributes to the development of multiple neoplasms, including MPNSTs.\"},{\"question\":\"Why are immune checkpoint blockade therapies difficult to apply to MPNSTs?\",\"answer\":\"The document states that MPNSTs are typically non–T cell–inflamed “cold” tumors. Because successful ICB outcomes require a T cell–enriched tumor microenvironment, cold tumors are less likely to generate effective antitumor responses to checkpoint inhibition.\"},{\"question\":\"How does STING activation improve response to immunotherapy in the described models?\",\"answer\":\"By activating STING signaling, the strategy converts MPNSTs into T cell–inflamed “hot” tumors. In mouse genetic and human xenograft models, combining a STING agonist with ICB produced growth delay associated with increased apoptotic cell death.\"}]","STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy | PDF",1790014384,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19746c82cf285bfe492761db50325d0c.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bf333e2b3c73e1748b6a7a33f67ed87.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22b99e6f1af4722768be637501c2f3cc.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/367a46814c19765a7cbec7488e388b28.webp",980,1311]